Listed

Relmada Therapeutics, Inc.: Form 10-K for the period ended Jun 30, 2016

Filed with the SEC on Sep 9, 2016 and accepted by EDGAR at Sep 9, 2016, 17:13 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2016-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development12 months2015-07-01 to 2016-06-30$6.2mus-gaap:ResearchAndDevelopmentExpense
Operating income12 months2015-07-01 to 2016-06-30−$16.2mus-gaap:OperatingIncomeLoss
Net income12 months2015-07-01 to 2016-06-30−$3.0mus-gaap:NetIncomeLoss
Diluted EPS12 months2015-07-01 to 2016-06-30−$0.26us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow12 months2015-07-01 to 2016-06-30−$13.1mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure12 months2015-07-01 to 2016-06-30$562.3kus-gaap:PaymentsToAcquireProductiveAssets
Cash and equivalentsAt period end2016-06-30$8.5mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2016-06-30$9.3mus-gaap:AssetsCurrent
Total assetsAt period end2016-06-30$10.2mus-gaap:Assets
Current liabilitiesAt period end2016-06-30$3.1mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2016-06-30$3.2mus-gaap:Liabilities
Shareholders' equityAt period end2016-06-30$7.0mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001213900-16-016664. Last ingested by Listed: Nov 13, 2026, 15:42 ET. Listed shows no prices and gives no investment advice.